The original CDC experiments on heat treatment had been conducted with Cutter's and Alpha's products and then Hyland asked CDC to conduct similar tests on their product, with similar results. Read more about The original CDC experiments on heat treatment had been conducted with Cutter's and Alpha's products and then Hyland asked CDC to conduct similar tests on their product, with similar results.
Alter et al in the article "The Ausria Test: Critical Evaluation of Sensitivity and Specificity" concluded that "the single most significant measure for the reduction of posttransfusion hepatitis is the total exclusion of the commercial donor." Read more about Alter et al in the article "The Ausria Test: Critical Evaluation of Sensitivity and Specificity" concluded that "the single most significant measure for the reduction of posttransfusion hepatitis is the total exclusion of the commercial donor."
In February 1986 the possibility that Factorate HT, Armour's heat-treated Factor 8 product, might have caused HIV transmission became widespread knowledge. Read more about In February 1986 the possibility that Factorate HT, Armour's heat-treated Factor 8 product, might have caused HIV transmission became widespread knowledge.
Alpha had a 22% level of hepatitis infection from commercial products at the start of 1986. Read more about Alpha had a 22% level of hepatitis infection from commercial products at the start of 1986.
It was reported that there was a higher risk of hepatitis from commercially obtained blood than from blood from unpaid donors. Read more about It was reported that there was a higher risk of hepatitis from commercially obtained blood than from blood from unpaid donors.
Although a universal Hepatitis B vaccine only began in the UK in 2017, a few children with haemophilia were vaccinated in the early 1980s. Read more about Although a universal Hepatitis B vaccine only began in the UK in 2017, a few children with haemophilia were vaccinated in the early 1980s.
Scotland was ahead of England and had started to heat Factor 8 stocks in a way which would inactivate HTLV-3 from 18 November 1984. Read more about Scotland was ahead of England and had started to heat Factor 8 stocks in a way which would inactivate HTLV-3 from 18 November 1984.
Dr Perry wrote to five Scottish regions and Belfast to tell them on 10 or 11 December they would be supplied with sufficient heat-treated product to cover a month and continuous supply would be made thereafter in sufficient quantities to enable non-heat-treated product to be recalled. Read more about Dr Perry wrote to five Scottish regions and Belfast to tell them on 10 or 11 December they would be supplied with sufficient heat-treated product to cover a month and continuous supply would be made thereafter in sufficient quantities to enable non-heat-treated product to be recalled.
Immuno, Vienna concentrated on a virucidal process to inactivate hepatitis viruses. This was announced to many of the UKHCDO Directors and Dr Craske at a meeting, and it was said the early results had been successful. Read more about Immuno, Vienna concentrated on a virucidal process to inactivate hepatitis viruses. This was announced to many of the UKHCDO Directors and Dr Craske at a meeting, and it was said the early results had been successful.
Dr Foster reported to the directors of SNBTS at their meeting that the Factor 8 concentrate being issued were derived from unscreened plasma, but it was anticipated the position would change soon. Read more about Dr Foster reported to the directors of SNBTS at their meeting that the Factor 8 concentrate being issued were derived from unscreened plasma, but it was anticipated the position would change soon.